Sign in

CIK 0001701108 · Non-accelerated filer<br>Smaller reporting company

Spero Therapeutics, Inc.

Sign in to watch
Ticker
SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
857-242-1600
Business address
675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139
Former names
Spero Therapeutics, LLC
  1. 4 Grant or award Director acquired 20,000 shares (grant or award)
  2. 4 Grant or award Director acquired 20,000 shares (grant or award)
  3. 4 Grant or award Director acquired 20,000 shares (grant or award)
  4. 4 Open-market sale Chief Medical Officer sold 39,496 shares at $1.27 ($50,160)
  5. 4 Open-market sale Chief Development Officer sold 1,854 shares at $1.26 ($2,336)
  6. 4 Open-market sale Chief Legal Officer sold 1,854 shares at $1.26 ($2,336)
  7. 4 Open-market sale Director sold 9,040 shares at $1.26 ($11,390)
  8. 4 Planned sale CEO and President sold 6,017 shares at an average $1.29 ($7,748)
  9. 4 Grant or award CEO and President acquired 266,000 shares (grant or award)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Grant or award Chief Medical Officer acquired 140,000 shares (grant or award)
  12. 4 Open-market sale CEO and President sold 12,286 shares at $1.81 ($22,238)
  13. 4 Open-market sale Chief Operating Officer sold 3,394 shares at $1.86 ($6,313)
  14. 4 Open-market sale Chief Legal Officer sold 3,394 shares at $1.86 ($6,313)
  15. 4 Open-market sale Chief Financial Officer sold 9,504 shares at $1.83 ($17,372)
  16. 4 Grant or award Chief Medical Officer acquired 265,957 shares (grant or award)
  17. 4 Grant or award CEO and President acquired 531,914 shares (grant or award)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 4 of 12 · 231 filings